Loading clinical trials...
Loading clinical trials...
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Johns Hopkins University
Collaborators
NCT07470151 · System Lupus Erythematosus(SLE), Scleroderma, and more
NCT06801119 · Systemic Lupus Erythematosus, Scleroderma, and more
NCT04402086 · Rheumatic Diseases, Adult Onset Still Disease, and more
NCT07256418 · Scleroderma
NCT07090226 · Systemic Scleroderma, Diffuse Cutaneous Scleroderma
Johns Hopkins
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions